This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
4F-MPH: Difference between revisions
>Mildcannibal m Grammatics |
>Lillith m Fixed a typo on pharmacology subsection, 4-FPMH -> 4F-MPH |
||
| Line 20: | Line 20: | ||
4F-MPH is thought to act primarily as a [[dopamine and norepinephrine]] [[reuptake inhibitor]], meaning it effectively boosts the levels of dopamine and norepinephrine [[neurotransmitters]] in the brain by binding to and partially blocking the transporter proteins that normally clear these catecholamines from the synaptic cleft. This allows dopamine and norepinephrine to accumulate within the reward pathways in the brain, resulting in stimulating and euphoric effects. | 4F-MPH is thought to act primarily as a [[dopamine and norepinephrine]] [[reuptake inhibitor]], meaning it effectively boosts the levels of dopamine and norepinephrine [[neurotransmitters]] in the brain by binding to and partially blocking the transporter proteins that normally clear these catecholamines from the synaptic cleft. This allows dopamine and norepinephrine to accumulate within the reward pathways in the brain, resulting in stimulating and euphoric effects. | ||
According to a pharmacological evaluation, the ''(±)-threo'' isomer of | According to a pharmacological evaluation, the ''(±)-threo'' isomer of 4F-MPH is 2.15 times more effective at dopamine reuptake inhibition, and 2.7 times more at norepinephrine reuptake inhibition, than its parent compound methylphenidate. The ''(±)-erythro'' isomer, however, is 65 times less effective at dopamine reuptake inhibition and 45.6 times less effective at norepinephrine reuptake inhibition than methylphenidate. Neither racemate of 4F-MPH has a significant impact on serotonin reuptake.<ref>Analytical characterization and pharmacological evaluation of the new psychoactive substance 4-fluoromethylphenidate (4F-MPH) and differentiation between the (±)-threo and (±)-erythro diastereomers | https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/dta.2167</ref> | ||
==Subjective effects== | ==Subjective effects== | ||
| Line 80: | Line 80: | ||
===Experience reports=== | ===Experience reports=== | ||
There are currently no anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here: | There are currently no anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here: | ||
* [https://www.erowid.org/experiences/subs/exp_4Fluoromethylphenidate.shtml Erowid Experience Vaults: 4-Fluoromethylphenidate] | |||
*[https://www.erowid.org/experiences/subs/exp_4Fluoromethylphenidate.shtml Erowid Experience Vaults: 4-Fluoromethylphenidate] | |||
==Toxicity and harm potential== | ==Toxicity and harm potential== | ||
| Line 97: | Line 98: | ||
{{DangerousInteractions/Intro}} | {{DangerousInteractions/Intro}} | ||
{{DangerousInteractions/Stimulants|self=4F-MPH}} | {{DangerousInteractions/Stimulants|self=4F-MPH}} | ||
{{DangerousInteractions/MAOI|nt=dopamine}} | {{DangerousInteractions/MAOI|nt=dopamine}} | ||
| Line 109: | Line 111: | ||
==See also== | ==See also== | ||
*[[Responsible use]] | *[[Responsible use]] | ||
*[[Designer drug]] | *[[Designer drug]] | ||
| Line 116: | Line 119: | ||
==External links== | ==External links== | ||
*[https://en.wikipedia.org/wiki/4-Fluoromethylphenidate 4F-MPH (Wikipedia)] | *[https://en.wikipedia.org/wiki/4-Fluoromethylphenidate 4F-MPH (Wikipedia)] | ||
*[https://isomerdesign.com/PiHKAL/explore.php?id=630 4F-MPH (Isomer Design)] | *[https://isomerdesign.com/PiHKAL/explore.php?id=630 4F-MPH (Isomer Design)] | ||